Clinical Trial Update: Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating duvelisib in Japanese patients with relapsed or refractory lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: AbbVie | Conditions: Lymphoma | Phase 1 | Status: COMPLETED